Is Lucid Diagnostics Stock a good buy in 2023, according to Wall Street analysts?
The consensus among 3 Wall Street analysts covering (NASDAQ: LUCD) stock is to Strong Buy LUCD stock.
Out of 3 analysts, 2 (66.67%) are recommending LUCD as a Strong Buy, 1 (33.33%) are recommending LUCD as a Buy, 0 (0%) are recommending LUCD as a Hold, 0 (0%) are recommending LUCD as a Sell, and 0 (0%) are recommending LUCD as a Strong Sell.
What is LUCD's forecast return on equity (ROE) for 2023-2023?
(NASDAQ: LUCD) forecast ROE is -2,638.8%, which is considered weak.
What is LUCD's Price Target?
According to 3 Wall Street analysts that have issued a 1 year LUCD price target, the average LUCD price target is $3.50, with the highest LUCD stock price forecast at $4.00 and the lowest LUCD stock price forecast at $2.50.
On average, Wall Street analysts predict that Lucid Diagnostics's share price could reach $3.50 by Nov 14, 2024. The average Lucid Diagnostics stock price prediction forecasts a potential upside of 155.47% from the current LUCD share price of $1.37.
What is LUCD's forecast return on assets (ROA) for 2023-2023?
(NASDAQ: LUCD) forecast ROA is -202.89%, which is lower than the forecast US Medical Devices industry average of 7.95%.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.